Success Story: EB1A Approved After Overcoming RFE! Our Firm Assisted a Postdoctoral Fellow in Securing Success
Client’s Testimonial:
"Thank you very much for your support throughout my petition process. I truly appreciate your professional guidance and assistance.”
On May 22nd, 2026, we received another EB-1A (Alien of Extraordinary Ability) approval for a Postdoctoral Fellow in the Field of Computational Biology (Approval Notice).
General Field: Computational Biology
Position at the Time of Case Filing: Postdoctoral Fellow
Country of Origin: China
State of Residence at the Time of Filing: Colorado
Approval Notice Date: May 22nd, 2026
Processing Time: 9 months and 14 days
Case Summary:
Our firm is pleased to share the successful approval for a postdoctoral fellow in computational biology in approximately 9 months and 14 days under premium processing. Holding a Ph.D. in electrical engineering, this researcher approached our firm seeking support in securing permanent residency through the EB1A (Alien of Extraordinary Ability) category.
After a thorough review of the achievements and impact presented, our expert team prepared a compelling petition that resulted in the approval of the I-140 EB1A filing. While an RFE was issued, our team promptly prepared a comprehensive response that highlighted not only the objective metrics of academic success but also the real-world impact of the work on cancer research, RNA biology, and biomedical data analysis. Through a carefully tailored strategy, we guided the researcher in further identifying and documenting the significance of his contributions and academic impact. This approval underscores an extraordinary level of influence in deep learning applications for cancer genomics and computational biology.
Accomplishments and Expertise
With a strong reputation as a leading researcher in computational biology, this postdoctoral fellow brings expertise spanning cancer research, genomic data analysis, and RNA biology. Much of the work focuses on applying advanced artificial intelligence and machine learning techniques to address critical challenges in disease mechanisms, diagnosis and treatment. These contributions have been especially influential in developing computational tools that support more accurate and personalized medical decision-making, directly benefiting patients and the U.S. healthcare system.
In support of the EB1A petition, we highlighted several objective achievements, including:
- 16 peer-reviewed journal articles (with 4 first-authored), 3 peer-reviewed conference papers
- 20 completed peer reviews
- 745 citations
- Participation in research projects supported by prestigious organizations, including the National Cancer Institute (NCI), National Institutes of Health (NIH), Cancer Prevention and Research Institute of Texas (CPRIT), and the National Science Foundation (NSF)
Letters of Recommendation
To further support the petition, we obtained three expert letters of recommendation from highly regarded professionals. One recommender stated:
“Ensuring that [Client]’s research continues without interruption is highly important for advancing our understanding of cancer through computational methods and for developing improved diagnostic and therapeutic strategies benefiting the U.S. healthcare system.”
EB1A Approval and Outlook
Our firm is honored to have represented this outstanding researcher in a successful EB1A petition and looks forward to seeing the continued contributions that will be made to advancing cancer genomics, RNA modification research, and AI-driven biomedical innovation in the United States. We extend our sincerest best wishes for continued success in both professional and personal pursuits.